Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Neoplasms 6Lymphoma, Non-Hodgkin 6Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neoplasm Metastasis 3Multiple Myeloma 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Small Cell Lung Carcinoma 2Skin Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2

Interventions

human papillomavirus vaccine, L1 type 16, 18 36Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 19Papillomavirus Vaccines 16Vaccines 10Data Collection 9Blood Specimen Collection 5Vaccines, Synthetic 4artesunic acid 3artemisinin 3Engerix-B 3halofantrine 2epigallocatechin gallate 2artenimol 2Hepatitis A Vaccines 2GX-188 vaccine 2Colposcopy 2ranpirnase 1fludarabine 1Viusid 1Vitamin B 12 1VP-102 1VGX-3100 1Therapies, Investigational 1Sodium Chloride 1Pentetic Acid 1Observation 1Methods 1Measles-Mumps-Rubella Vaccine 1Interleukin-2 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Papillomavirus Infections × Interleukin-2 × Clear all
NCT03912831 2023-12-26

Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

Gilead Sciences

Phase 1 Terminated
8 enrolled 13 charts

Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡